论文部分内容阅读
目的:观察并探讨前列舒通胶囊联合盐酸莫西沙星治疗慢性前列腺炎的临床疗效。方法:将2010年2月—2012年2月入院的慢性前列腺炎患者180例随机分为对照组和试验组,试验组100例,采用前列舒通胶囊联合盐酸莫西沙星治疗;对照组80例,采用单纯莫西沙星治疗。治疗前后对所有患者行NIH-CPSI评分及前列腺液常规检查。治疗1个月后,复诊比较两组患者临床疗效,NIH-CPSI评分及前列腺液白细胞计数变化。结果:试验组总有效率(91.00%)显著高于对照组(72.50%),两者之间差异有显著性(P<0.05)。2组患者治疗前NIH-CPSI评分及前列腺液白细胞计数无显著性差异,而治疗后NIH-CPSI评分及前列腺液白细胞计数均较治疗前有所降低,其中试验组显著低于对照组,两者之间具有统计学差异(P<0.05)。结论:前列舒通胶囊联合盐酸莫西沙星治疗慢性前列腺炎临床疗效显著。
Objective: To observe and discuss the clinical efficacy of Qianlieshutong capsule combined with moxifloxacin hydrochloride in the treatment of chronic prostatitis. Methods: One hundred and eighty patients with chronic prostatitis admitted from February 2010 to February 2012 were randomly divided into control group and trial group. 100 cases in trial group were treated with Qianlieshutong capsule combined with moxifloxacin hydrochloride and 80 cases in control group , The use of simple moxifloxacin treatment. Before and after treatment for all patients NIH-CPSI score and prostatic fluid routine examination. After 1 month of treatment, the clinical outcomes, NIH-CPSI score and prostatic fluid leukocyte count were compared between the two groups. Results: The total effective rate (91.00%) in the experimental group was significantly higher than that in the control group (72.50%), the difference was significant (P <0.05). There was no significant difference in NIH-CPSI score and prostatic fluid leukocyte count before treatment in both groups, but NIH-CPSI score and prostatic fluid leukocyte count decreased after treatment, in which the test group was significantly lower than the control group, both There was a statistically significant difference (P <0.05). Conclusion: Qianlieshutong capsule combined with moxifloxacin hydrochloride has obvious curative effect on chronic prostatitis.